Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

57
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
57
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

92
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
92
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

77
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
77
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

74
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
74
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

1.5K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.5K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

334
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
334

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of bladder wash for postmortem toxicological analysis: Comparison with urine in 50 forensic cases.

International journal of legal medicine·2026
Same author

N-Ethylpentedrone: first hair detection and human metabolic profiling across multiple biological matrices using UHPLC-HRMS, molecular networking and in silico prediction.

Archives of toxicology·2026
Same author

Lentiviral-mediated expression of cytochrome P450 2D6 in HepaRG cells: new means for in vitro xenobiotic biotransformation and cellular response to chimeric viral mRNA.

Archives of toxicology·2026
Same author

Influence of hepatic steatosis on antiseizure drug metabolism: in vitro evidence from differentiated HepaRG cells.

Toxicology letters·2026
Same author

Mapping the human chemical exposome for public health.

Nature medicine·2026
Same author

Multi-Cellular Human Liver Organoids for Modeling Metabolic Dysfunction-Associated Steatotic Liver Disease and Drug-Induced Liver Injury.

Current protocols·2026

Related Experiment Video

Updated: Nov 12, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K

[Once upon a time the hepatotoxicity…].

Brendan Le Daré1, Pierre-Jean Ferron2, Thomas Gicquel1

  • 1Univ Rennes, Inserm, INRAE, CHU de Rennes, Institut Nutrition, métabolisme et cancer (NuMeCan), Réseau PREVITOX, F-35000 Rennes, France - CHU de Rennes, Laboratoire de toxicologie biomédicale et médico-légale, 2 rue Henri Le Guilloux, F-35000 Rennes, France.

Medecine Sciences : M/S
|March 19, 2021
PubMed
Summary

The liver metabolizes many compounds but is also vulnerable to toxic damage. Understanding idiosyncratic hepatotoxicity is crucial for predicting and preventing unpredictable liver injury.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.2K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:31

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

143

Related Experiment Videos

Last Updated: Nov 12, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.2K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:31

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

143

Area of Science:

  • Hepatology
  • Toxicology
  • Immunology

Background:

  • The liver's extensive enzymatic equipment, vascularization, and anatomical position facilitate xenobiotic metabolism but also render it susceptible to toxic compounds.
  • Xenobiotics-induced hepatotoxicity is a significant cause of liver damage, posing challenges for clinicians, the pharmaceutical industry, and health agencies.
  • Hepatotoxicity is broadly classified into intrinsic (predictable, dose-dependent) and idiosyncratic (unpredictable, susceptibility-based) forms.

Purpose of the Study:

  • To highlight the challenges posed by xenobiotics-induced hepatotoxicity.
  • To emphasize the unclear pathophysiology of idiosyncratic immune-mediated hepatotoxicity.
  • To underscore the need for improved tools for predicting and understanding these adverse drug reactions.

Main Methods:

  • Review of existing literature on liver metabolism and xenobiotics.
  • Distinction between intrinsic and idiosyncratic hepatotoxicity mechanisms.
  • Discussion of the current understanding and challenges in idiosyncratic immune-mediated hepatotoxicity.

Main Results:

  • The liver's metabolic functions also make it a primary target for toxic insults.
  • Idiosyncratic hepatotoxicity, particularly immune-mediated forms, lacks clear pathophysiological understanding.
  • Current tools for prediction and understanding of idiosyncratic hepatotoxicity are insufficient.

Conclusions:

  • Developing better tools is essential for identifying risk factors and novel mechanisms of idiosyncratic hepatotoxicity.
  • Further research into idiosyncratic immune-mediated hepatotoxicity is critical for clinical management and drug safety.
  • Addressing xenobiotics-induced liver damage requires a deeper understanding of individual susceptibility and immune responses.